section name header

Indications ⬇

REMS


Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

Route/Dosage ⬆ ⬇

US Brand Names ⬆ ⬇

Joenja

Action ⬆ ⬇

  • Acts as an inhibitor of phosphatidylinositol 3-kinase-delta, thereby inhibiting the signaling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and dysregulation of B and T cells.
Therapeutic effects:

Classifications ⬆ ⬇

Therapeutic Classification: none assigned

Pharmacologic Classification: kinase inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: Unknown.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP3A4 isoenzyme, and minor contribution by the CYP3A5, CYP1A2, and CYP2D6 isoenzymes. Primarily excreted in the feces (67%), with 25.5% excreted in the urine.

Half-Life: 10 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
POrapid1 hr12 hr

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆

LEN-i-oh-LIS-ib